1
Home
Companies

Wockhardt Bio AG

Wockhardt Bio AG
Leadership team

Dr. Habil Fakhruddin Khorakiwala (Founder & Exec. Chairman)

Dr. Murtaza Habil Khorakiwala (MD & Exec. Director)

Dr. Huzaifa Habil Khorakiwala (Exec. Director)

Products/ Services
Biopharma, Biotechnology, Health Care, Life Science, Manufacturing, Medical, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Zug, Zug, Switzerland
Established
2005
Revenue
100M - 500M
Traded as
BX:WBIO
URL
https://www.wockhardt.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia, and internationally. It develops various molecules primarily in the areas of infectious diseases, such as WCK 5222, WCK 4282, WCK 4873, WCK 771 and WCK 2349, and WCK 6777 molecules. The company's biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. It also provides contract manufacturing services for sterile injectables, lyophilization, and other dosage forms; and research services. The company was founded in 1967 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited.
History

Wockhardt was founded by Dr. Habil Khorakiwala in the 1960s. His father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works in 1959. This was incorporated as Wockhardt Pvt. Ltd., in 1973. Wockhardt Ltd. was incorporated on 8 July 1999. In the 1990s, Wockhardt gained market share with its painkiller Proxyvon and blood pressure drugs . In 1995, it expanded into biotechnology, and subsequently started producing intravenous fluids.Wockhardt is the first company outside the US and Europe to manufacture recombinant human insulin.During the COVID-19 pandemic, Wockhardt signed a contract with the Government of the United Kingdom to fill-finish the Oxford–AstraZeneca COVID-19 vaccine at the company's facility in Wrexham, Wales. The contract was extended until August 2022.In August 2021, Wockhardt announced that it signed an agreement with Dubai-based Enso Healthcare and Russian firm Human Vaccine LLC to contract manufacture the Sputnik V and Sputnik Light vaccines in India.The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France.

Mission
The mission at Wockhardt Bio AG is to develop innovative, affordable and responsible healthcare products that make a difference in the lives of patients around the world.
Vision
The vision at Wockhardt Bio AG is to become the leader in the field of life sciences and healthcare, providing innovative products and services that meet the needs of both patients and clinical professionals.
Key Team

Ms. Pradnya Deshmukh (Pres and Global Head of Quality & Compliance)

Mr. Deepak Madnani (Chief Financial Officer)

Mr. Prem Singh (Pres of Global HR)

Mr. Anil V. Kamath AMRSH (Lon.), BCom (Hons), MBIM (Lon.), MIMA (Sr. VP of Bus. Devel.)

Mr. Georg Cubuk (Managing Director of Esparma - Germany)

Mr. Sunil Kumar Khera (Pres of Americas, Emerging Market & Japan)

Mr. Zoher T. Sihorwala (Head of Global Regulatory Affairs)

Recognition and Awards
Wockhardt Bio AG has won numerous awards, including the 2019 Pharmaceutical Technology & Innovation Award, the 2018 Financial Times Innovative Pharmaceutical Company Award, and the Best Biotechnology Company Award at the 2018 World Pharma Expo.
References

https://en.wikipedia.org/wiki/Wockhardt

https://in.investing.com/equities/wockhardt

https://finance.yahoo.com/quote/WOCKPHARMA.NS/profile?p=WOCKPHARMA.NS

https://www.crunchbase.com/organization/wockhardt-bio-ag

https://www.wockhardt.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Wockhardt Bio AG
Leadership team

Dr. Habil Fakhruddin Khorakiwala (Founder & Exec. Chairman)

Dr. Murtaza Habil Khorakiwala (MD & Exec. Director)

Dr. Huzaifa Habil Khorakiwala (Exec. Director)

Products/ Services
Biopharma, Biotechnology, Health Care, Life Science, Manufacturing, Medical, Pharmaceutical
Number of Employees
1,000 - 20,000
Headquarters
Zug, Zug, Switzerland
Established
2005
Revenue
100M - 500M
Traded as
BX:WBIO
URL
https://www.wockhardt.com